AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo Company announced that the FDA has granted accelerated approval to their antibody drug conjugate candidate, trastuzumab deruxtecan for metatstaic breast cancer. The drug will be available as monotherapy for unresectable or metastatic HER2-positive breast cancer in patients who have …
News story posted on 2019-12-23T17:45:00.0000000Z
